[{"id":"b44521d2-5829-4bf3-b6c2-ad08cfcaf642","acronym":"","url":"https://clinicaltrials.gov/study/NCT06863805","created_at":"2025-07-19T14:06:15.287Z","updated_at":"2025-07-19T14:06:15.287Z","phase":"","brief_title":"Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas","source_id_and_acronym":"NCT06863805","lead_sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","biomarkers":" BRAF • ALK • RET • RAS • NTRK","pipe":" | ","alterations":" RAS mutation • RET mutation","tags":["BRAF • ALK • RET • RAS • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation • RET mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-03-07"},{"id":"b7e46662-a1fb-4cfe-bc8c-ef3263bb5749","acronym":"PANIRINOX","url":"https://clinicaltrials.gov/study/NCT02980510","created_at":"2021-01-18T14:39:41.163Z","updated_at":"2025-02-25T13:52:12.814Z","phase":"Phase 2","brief_title":"Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients","source_id_and_acronym":"NCT02980510 - PANIRINOX","lead_sponsor":"UNICANCER","biomarkers":" KRAS • RAS","pipe":"","alterations":" ","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 219","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-20"},{"id":"fb4d840f-ccf1-4e5e-ac00-2c10191c007e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554367","created_at":"2022-09-26T14:56:10.119Z","updated_at":"2025-02-25T13:54:43.263Z","phase":"Phase 2","brief_title":"Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554367","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • RAS","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12","tags":["KRAS • BRAF • NRAS • HRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Mektovi (binimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 08/26/2026","primary_completion_date":" 08/26/2026","study_txt":" Completion: 08/26/2026","study_completion_date":" 08/26/2026","last_update_posted":"2025-02-20"},{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"},{"id":"5895dd46-f4f2-46c6-9499-4596f2c29417","acronym":"","url":"https://clinicaltrials.gov/study/NCT06011772","created_at":"2023-08-25T15:08:32.780Z","updated_at":"2025-02-25T14:03:46.296Z","phase":"Phase 1","brief_title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06011772","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" KRAS • BRAF • RAS","pipe":" | ","alterations":" BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type","tags":["KRAS • BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 12/04/2023","start_date":" 12/04/2023","primary_txt":" Primary completion: 12/04/2025","primary_completion_date":" 12/04/2025","study_txt":" Completion: 12/04/2026","study_completion_date":" 12/04/2026","last_update_posted":"2025-02-19"},{"id":"a5794ed7-ec20-4c8e-af55-9e059e2c03e3","acronym":"RASolute 302","url":"https://clinicaltrials.gov/study/NCT06625320","created_at":"2025-02-25T14:19:38.953Z","updated_at":"2025-02-25T14:19:38.953Z","phase":"Phase 3","brief_title":"Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)","source_id_and_acronym":"NCT06625320 - RASolute 302","lead_sponsor":"Revolution Medicines, Inc.","biomarkers":" RAS","pipe":" | ","alterations":" RAS mutation","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • daraxonrasib (RMC-6236)"],"overall_status":"Recruiting","enrollment":" Enrollment 460","initiation":"Initiation: 10/16/2024","start_date":" 10/16/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-17"},{"id":"b830c833-61a0-434d-8a29-24074697ffb9","acronym":"DURAFAK","url":"https://clinicaltrials.gov/study/NCT05512208","created_at":"2022-08-23T14:55:32.872Z","updated_at":"2025-02-25T15:27:34.112Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib","source_id_and_acronym":"NCT05512208 - DURAFAK","lead_sponsor":"University of Oklahoma","biomarkers":" BRAF • NF1 • RAS","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF • NF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 02/06/2023","start_date":" 02/06/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-02-10"},{"id":"586870f5-0132-4c9b-9469-6d1bb21374ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT05278728","created_at":"2022-03-14T13:54:05.742Z","updated_at":"2025-02-25T16:32:54.217Z","phase":"Phase 1/2","brief_title":"Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer","source_id_and_acronym":"NCT05278728","lead_sponsor":"Biotech Pharmaceutical Co., Ltd.","biomarkers":" KRAS • RAS","pipe":"","alterations":" ","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • TheraCIM (nimotuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 07/01/2009","start_date":" 07/01/2009","primary_txt":" Primary completion: 08/01/2013","primary_completion_date":" 08/01/2013","study_txt":" Completion: 12/01/2013","study_completion_date":" 12/01/2013","last_update_posted":"2025-02-07"},{"id":"29c59c3c-4af3-4d3c-bbe9-82bcfe995e5f","acronym":"CAIRO5","url":"https://clinicaltrials.gov/study/NCT02162563","created_at":"2021-01-18T10:04:04.928Z","updated_at":"2025-02-25T16:36:23.493Z","phase":"Phase 3","brief_title":"Treatment Strategies in Colorectal Cancer Patients with Initially Unresectable Liver-only Metastases","source_id_and_acronym":"NCT02162563 - CAIRO5","lead_sponsor":"Dutch Colorectal Cancer Group","biomarkers":" BRAF • RAS","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 530","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 07/01/2022","primary_completion_date":" 07/01/2022","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2025-02-06"},{"id":"7460cc37-d435-44b0-a888-a97d57a2e6c3","acronym":"START-001","url":"https://clinicaltrials.gov/study/NCT05592626","created_at":"2022-10-24T13:57:11.728Z","updated_at":"2025-02-25T17:31:39.938Z","phase":"Phase 1/2","brief_title":"A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT05592626 - START-001","lead_sponsor":"Marengo Therapeutics, Inc.","biomarkers":" KRAS • TMB • MSI • RAS","pipe":" | ","alterations":" KRAS mutation • TMB-H • MSI-H/dMMR • RAS mutation • RAS wild-type","tags":["KRAS • TMB • MSI • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • MSI-H/dMMR • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e invikafusp alfa (STAR0602)"],"overall_status":"Recruiting","enrollment":" Enrollment 365","initiation":"Initiation: 01/04/2023","start_date":" 01/04/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-01-30"},{"id":"c140a8b8-ac68-4df9-988d-ebe6e54e87b6","acronym":"DETERMINE","url":"https://clinicaltrials.gov/study/NCT06194929","created_at":"2024-01-08T19:20:11.355Z","updated_at":"2025-02-25T17:32:44.459Z","phase":"Phase 1/2","brief_title":"Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma","source_id_and_acronym":"NCT06194929 - DETERMINE","lead_sponsor":"University of Utah","biomarkers":" NF1 • RAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation","tags":["NF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Braftovi (encorafenib) • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 03/07/2024","start_date":" 03/07/2024","primary_txt":" Primary completion: 01/15/2028","primary_completion_date":" 01/15/2028","study_txt":" Completion: 01/15/2030","study_completion_date":" 01/15/2030","last_update_posted":"2025-01-30"},{"id":"a0cf279a-8d5c-46c3-9bca-6f57de2820c1","acronym":"NAUTICALCRC","url":"https://clinicaltrials.gov/study/NCT05004350","created_at":"2021-08-13T12:53:27.664Z","updated_at":"2025-02-25T16:16:36.860Z","phase":"Phase 2","brief_title":"A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.","source_id_and_acronym":"NCT05004350 - NAUTICALCRC","lead_sponsor":"Pierre Fabre Medicament","biomarkers":" BRAF • MSI • CEACAM5 • RAF1 • RAS • CA 19-9","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • RAS mutation • RAS wild-type","tags":["BRAF • MSI • CEACAM5 • RAF1 • RAS • CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • irinotecan • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 09/14/2021","start_date":" 09/14/2021","primary_txt":" Primary completion: 12/19/2023","primary_completion_date":" 12/19/2023","study_txt":" Completion: 01/11/2025","study_completion_date":" 01/11/2025","last_update_posted":"2024-06-18"},{"id":"f7f0dd30-c5fe-4b5b-bd30-831480836846","acronym":"ARMANI","url":"https://clinicaltrials.gov/study/NCT04678583","created_at":"2021-01-19T20:46:12.268Z","updated_at":"2024-07-02T16:34:26.543Z","phase":"","brief_title":"Anatomical Resection of Liver MetAstases iN patIents With RAS-mutated Colorectal Cancer","source_id_and_acronym":"NCT04678583 - ARMANI","lead_sponsor":"Technische Universität Dresden","biomarkers":" KRAS • NRAS • RAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • RAS mutation","tags":["KRAS • NRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • RAS mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-06-13"},{"id":"285e0fae-6b50-4026-b6af-15e5137223d2","acronym":"ZWI-ZW25-201","url":"https://clinicaltrials.gov/study/NCT03929666","created_at":"2021-01-18T19:21:37.373Z","updated_at":"2024-07-02T16:34:37.769Z","phase":"Phase 2","brief_title":"A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer","source_id_and_acronym":"NCT03929666 - ZWI-ZW25-201","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" HER-2 • KRAS • BRAF • NRAS • RAS","pipe":" | ","alterations":" HER-2 amplification • HER-2 expression • KRAS wild-type • BRAF wild-type • NRAS wild-type","tags":["HER-2 • KRAS • BRAF • NRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 expression • KRAS wild-type • BRAF wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • gemcitabine • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Ziihera (zanidatamab-hrii)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/29/2019","start_date":" 08/29/2019","primary_txt":" Primary completion: 11/28/2025","primary_completion_date":" 11/28/2025","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2024-06-06"},{"id":"a3759a52-c4d8-4024-b32b-cdbe20861361","acronym":"","url":"https://clinicaltrials.gov/study/NCT05239741","created_at":"2022-02-15T16:53:10.993Z","updated_at":"2024-07-02T16:35:00.681Z","phase":"Phase 3","brief_title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","source_id_and_acronym":"NCT05239741","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" BRAF • MSI • RAS","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation • RAS mutation • RAS wild-type","tags":["BRAF • MSI • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation • RAS mutation • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/02/2022","start_date":" 04/02/2022","primary_txt":" Primary completion: 11/10/2026","primary_completion_date":" 11/10/2026","study_txt":" Completion: 11/10/2026","study_completion_date":" 11/10/2026","last_update_posted":"2024-05-27"},{"id":"f2ecb3f0-ab29-45ec-8263-60d2706b0d8a","acronym":"BACCI","url":"https://clinicaltrials.gov/study/NCT02873195","created_at":"2022-06-29T09:01:25.253Z","updated_at":"2024-07-02T16:35:00.701Z","phase":"Phase 2","brief_title":"Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02873195 - BACCI","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" RAS","pipe":" | ","alterations":" RAS wild-type","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • capecitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 07/07/2017","start_date":" 07/07/2017","primary_txt":" Primary completion: 03/06/2023","primary_completion_date":" 03/06/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-05-27"},{"id":"d4b81b99-d243-4c1f-add1-f65829f75ba3","acronym":"C-PRECISE-01","url":"https://clinicaltrials.gov/study/NCT04495621","created_at":"2021-01-18T21:35:30.672Z","updated_at":"2024-07-02T16:35:03.454Z","phase":"Phase 1/2","brief_title":"MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)","source_id_and_acronym":"NCT04495621 - C-PRECISE-01","lead_sponsor":"Menarini Group","biomarkers":" KRAS • BRAF • PIK3CA • RAS","pipe":" | ","alterations":" BRAF mutation • PIK3CA mutation • BRAF wild-type","tags":["KRAS • BRAF • PIK3CA • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • PIK3CA mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • izorlisib (MEN1611)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 07/20/2020","start_date":" 07/20/2020","primary_txt":" Primary completion: 01/12/2024","primary_completion_date":" 01/12/2024","study_txt":" Completion: 02/27/2024","study_completion_date":" 02/27/2024","last_update_posted":"2024-05-15"},{"id":"5d8dc41e-ef67-4385-b4da-7bcfa8dfaa3c","acronym":"PERSEIDA","url":"https://clinicaltrials.gov/study/NCT02792478","created_at":"2021-01-18T13:42:27.872Z","updated_at":"2024-07-02T16:35:04.096Z","phase":"","brief_title":"Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study","source_id_and_acronym":"NCT02792478 - PERSEIDA","lead_sponsor":"Amgen","biomarkers":" BRAF • RAS","pipe":" | ","alterations":" RAS mutation • RAS wild-type","tags":["BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation • RAS wild-type"],"overall_status":"Completed","enrollment":" Enrollment 238","initiation":"Initiation: 05/06/2016","start_date":" 05/06/2016","primary_txt":" Primary completion: 05/31/2021","primary_completion_date":" 05/31/2021","study_txt":" Completion: 05/31/2021","study_completion_date":" 05/31/2021","last_update_posted":"2024-05-13"},{"id":"2d523b6b-3157-43c4-8a1d-6181d0102943","acronym":"VALIDATE","url":"https://clinicaltrials.gov/study/NCT03043950","created_at":"2022-06-29T09:01:42.720Z","updated_at":"2024-07-02T16:35:07.800Z","phase":"","brief_title":"Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)","source_id_and_acronym":"NCT03043950 - VALIDATE","lead_sponsor":"iOMEDICO AG","biomarkers":" RAS","pipe":"","alterations":" ","tags":["RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Vectibix (panitumumab) • irinotecan • leucovorin calcium"],"overall_status":"Completed","enrollment":" Enrollment 647","initiation":"Initiation: 01/25/2017","start_date":" 01/25/2017","primary_txt":" Primary completion: 01/17/2024","primary_completion_date":" 01/17/2024","study_txt":" Completion: 01/17/2024","study_completion_date":" 01/17/2024","last_update_posted":"2024-04-24"},{"id":"6cbfa766-eb96-4e2b-9a15-702ecd9edfeb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03206151","created_at":"2021-01-18T15:48:12.611Z","updated_at":"2024-07-02T16:35:10.411Z","phase":"Phase 3","brief_title":"CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03206151","lead_sponsor":"Taizhou Mabtech Pharmaceutical Co.,Ltd","biomarkers":" BRAF • RAS","pipe":" | ","alterations":" BRAF wild-type","tags":["BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • fluorouracil topical • Enlituo (cetuximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 520","initiation":"Initiation: 12/12/2017","start_date":" 12/12/2017","primary_txt":" Primary completion: 05/06/2022","primary_completion_date":" 05/06/2022","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-04-10"},{"id":"1daf6999-85a4-40e2-a654-9f006189a6d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT02395016","created_at":"2021-01-18T11:25:27.200Z","updated_at":"2024-07-02T16:35:11.490Z","phase":"Phase 3","brief_title":"A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02395016","lead_sponsor":"Biotech Pharmaceutical Co., Ltd.","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • TheraCIM (nimotuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 04/01/2015","start_date":" 04/01/2015","primary_txt":" Primary completion: 11/01/2021","primary_completion_date":" 11/01/2021","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2024-04-04"},{"id":"0ff46655-3196-4e55-a296-9ffdaa5cc8b1","acronym":"UTAH","url":"https://clinicaltrials.gov/study/NCT04145297","created_at":"2021-01-18T20:14:00.569Z","updated_at":"2024-07-02T16:35:13.869Z","phase":"Phase 1","brief_title":"Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas","source_id_and_acronym":"NCT04145297 - UTAH","lead_sponsor":"University of Utah","biomarkers":" KRAS • BRAF • HRAS • RAS","pipe":" | ","alterations":" BRAF mutation","tags":["KRAS • BRAF • HRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523) • hydroxychloroquine"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/17/2020","start_date":" 03/17/2020","primary_txt":" Primary completion: 06/10/2022","primary_completion_date":" 06/10/2022","study_txt":" Completion: 08/18/2022","study_completion_date":" 08/18/2022","last_update_posted":"2024-03-20"},{"id":"9efaf1c1-aab7-4353-870f-d5480b4a1d72","acronym":"","url":"https://clinicaltrials.gov/study/NCT01787500","created_at":"2021-01-17T17:23:41.948Z","updated_at":"2024-07-02T16:35:13.928Z","phase":"Phase 1","brief_title":"Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT01787500","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • RAS","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • RAS wild-type • BRAF positive","tags":["KRAS • BRAF • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • RAS wild-type • BRAF positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Zelboraf (vemurafenib) • irinotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/15/2013","start_date":" 02/15/2013","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-03-20"},{"id":"51c1d51d-fdcf-48b3-89a6-bab02f099fa5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02022982","created_at":"2021-01-18T09:16:01.874Z","updated_at":"2025-02-25T15:32:58.874Z","phase":"Phase 1","brief_title":"PALBOCICLIB + PD-0325901 for NSCLC \u0026 Solid Tumors","source_id_and_acronym":"NCT02022982","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Gomekli (mirdametinib)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 06/30/2021","study_completion_date":" 06/30/2021","last_update_posted":"2024-03-19"}]